Posts Archive for February 2010

Eye problems

Feb.21, 2010

Eye problems

Eye problems according to statical data are some of the most common problems which affect human health. In our fast-evolving society we can clearly see that amongst all the positive features a personal computer has it also inflicts damage to our eyesight and the most frequent cause of eye problems is sedentary work with a computer. When adults or children are performing certain tasks which are connected with eye stress, their eyes are fatigued, that if not alternated with eye exercise leads to certain common eye problems like:

Lamictal. New Lamictal medication is approved by FDA

Feb.12, 2010

Lamictal

FDA approved Lamictal in the form of extended release tablets for the treatment of generalized tonic-clonic seizures

US Food and Drug Administration (FDA) approved the extension of lamotrigine indications in the form of extended-release tablets (Lamictal made by GlaxoSmithKline) as adjuvant treatment of generalized tonic-clonic seizures once daily in patients aged 13 years and older .

FDA decision is based on the results of a double-blind multi-center clinical trial lasting 19 weeks which involved 143 patients.

Children autism

Feb.12, 2010

Children autism

According to extensive research conducted in the United States, a mature age of the mother increases the risk of autism in a child, regardless of age of his father.

Scientists have shown that increasing maternal age by 5 years is associated with increased risk of autism in children by 18%. Thus, for a woman who became a mother at the age of 40 years, the risk of birth of child with autism is 100% higher than in women in 25 years of age.

Tykerb. FDA approved the extension of Tykerb indications

Feb.09, 2010

Tykerb

Tykerb

Tykerb

Food and Drug Administration USA (FDA) approved the extension of the indications for drug Tykerb (lapatinib). Tykerb is approved now as one of the most progressive drug in combination with letrozole for the treatment of hormone-receptor-positive metastatic breast cancer with overexpression HER2 after the menopause period.

FDA decision is based on the results of a double-blind, placebo-controlled study, in which were involved 219 women in the period after menopause with estrogen-receptor-positive metastatic breast cancer with overexpression of HER2. The study showed that the use of letrozole and lapainiba  leads to increasing of survivability by 5.2 months in comparison with letrozole monotherapy.

Approval of this combination can help women suffering from the disease to avoid the use  of severe cytotoxic chemotherapy.

Nearly 60% to 70% of all cases of breast cancer in Europe and the U.S. are estrogen-receptor-positive, and 25% to 30% – with the overexpression of HER2.

Tykerb has already been approved in combination with Xeloda (capecitabine) for the treatment of hormone-receptor-positive metastatic breast cancer with HER2 overexpression by patients who received anthracycline,  taxane and trastuzumab therapy.

Tykerb (lapatinib) is manufactured by pharmaceutical company GlaxoSmithKline.

Oleptro. Oleptro drug in the treatment of major depressive disorder has been recently approved by US FDA

Feb.09, 2010

US Food and Drug Administration (FDA) approved medication Oleptro (trazadone hydrochloride) in the form of extended release tablets for use once daily in the treatment of depressive disorders in adults. Oleptro was launched by the pharmaceutical company Labopharm.

Oletpro is approved to treat major depressive disorder (MDD).